Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 392 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus (HIV) Positive Clear all
Completed Phase 2 Interventional

A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir

NCT00002452
View directory record Official record
Conditions
HIV Infections
Interventions
L-756423, Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

NCT00000886
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 C4-V3 Polyvalent Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
3
States / cities
Rochester, New York • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Recruiting Not applicable Interventional

Positive Peers Intervention Clinical Trial

NCT06388109
View directory record Official record
Conditions
HIV Infections
Interventions
Positive Peers mobile app
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
13 Years to 34 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Van Nuys, California • Newark, New Jersey • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplements for HIV-positive Patients on cART

NCT01295034
View directory record Official record
Conditions
HIV-associated Co-morbidities
Interventions
conventional vitamin D treatment, tiered/titrated vitamin D dosing
Dietary Supplement · Drug
Lead sponsor
Andrea Branch
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

NCT00000952
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 2 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
12
States / cities
Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

NCT00001036
View directory record Official record
Conditions
HIV Infections
Interventions
Thymalfasin, Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional

Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX

NCT01629316
View directory record Official record
Conditions
HIV Infection
Interventions
Text reminders, counseling, and link coordination, Standard of care - control arm
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 15, 2026, 11:40 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

NCT00131560
View directory record Official record
Conditions
HIV Infection
Interventions
VRX496-Modified Autologous T cells
Genetic
Lead sponsor
VIRxSYS Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
5
States / cities
Palo Alto, California • Norwalk, Connecticut • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 15, 2026, 11:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Blood for Multiple Collaborative Studies

NCT01336855
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Study of MDL 28,574A in HIV-Infected Patients

NCT00002329
View directory record Official record
Conditions
HIV Infections
Interventions
Celgosivir hydrochloride
Drug
Lead sponsor
Hoechst Marion Roussel
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

NCT03446573
View directory record Official record
Conditions
HIV Infections
Interventions
DTG + 3TC, TAF based regimen (TBR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
54
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM

NCT03432819
View directory record Official record
Conditions
HIV
Interventions
Siempre Seguiré
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 15, 2026, 11:40 AM EDT
Terminated Phase 4 Interventional

Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

NCT00234962
View directory record Official record
Conditions
HIV Infection
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2008 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

NCT00334659
View directory record Official record
Conditions
HIV Infections
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 15, 2026, 11:40 AM EDT
Terminated Not applicable Interventional Results available

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study

NCT00344487
View directory record Official record
Conditions
HIV
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CCTG 593: Testing and Linkage to Care

NCT01941121
View directory record Official record
Conditions
HIV Positive, HIV Seronegative
Interventions
Linkage to PrEP or Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
3
States / cities
Long Beach, California • Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

NCT00000879
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 3 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
17
States / cities
Long Beach, California • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Completed No phase listed Observational

Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy

NCT00286767
View directory record Official record
Conditions
Immune Reconstitution Inflammatory Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

NCT00272493
View directory record Official record
Conditions
HIV Infections
Interventions
Hepatitis B virus vaccine with GM-CSF adjuvant, Hepatitis B virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2008
U.S. locations
11
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

NCT02059499
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
Interventions
imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention

NCT01752504
View directory record Official record
Conditions
HIV Infection
Interventions
Community Mobilization
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin

NCT00000778
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyridoxine hydrochloride, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 15, 2026, 11:40 AM EDT